首页> 外文期刊>Nephron >Drug Dosing and Estimated Renal Function - Any Step Forward from Effersoe?
【24h】

Drug Dosing and Estimated Renal Function - Any Step Forward from Effersoe?

机译:药物给药和估计的肾功能 - 从expersoe前进的任何一步?

获取原文
获取原文并翻译 | 示例

摘要

Drug dosing in accordance with the renal function is a long-standing challenge to clinicians. For many years it has been evident that in many clinical situations there is no easy way to correctly dose any drug that is mainly cleared by the kidneys. Despite the development of many formulas for estimating the glomerular filtration rate, they all have serious shortcomings. Much effort has been put in to develop estimation formulas to evaluate the renal function as an alternative to direct methods with the aim of safely dosing drugs that are mainly cleared by the kidneys. Both creatinine- and cystatin C-based formulas with additional clinical and biochemical parameters deduced from association studies with methods to measure the glomerular filtration rate (mGFR) have been developed. None of them have been good enough to perform safely in the wide range of situations in daily clinical praxis. Despite serious limitations, there has also been a tendency to use estimated GFR (eGFR) as a "hard" clinical endpoint in clinical studies. This has increased the risk of misinterpretation and has led to conclusions that are not necessarily supported by data. Finally, new methods of testing drug toxicity and the use of pharmacological support in order to fix the right doses are mentioned in this short overview of studies; possible problems that are encountered using eGFR instead of mGFR in the clinic and in research are also mentioned in this report. (C) 2017 S. Karger AG, Basel
机译:根据肾功能的药物给药是对临床医生的长期挑战。多年来一直很明显,在许多临床情境中,没有容易给出任何主要被肾脏清除的药物的方法。尽管发展了许多用于估算肾小球过滤率的公式,但它们都有严重的缺点。已经努力开发估算公式,以评估肾功能,作为指导方法的替代方案,目的是安全使用的药物,这些药物主要被肾脏清除。已经开发出与测量肾小球过滤速率(MGFR)的结合研究引用的肌酸酐和胱抑素C的含有基于临床和生化参数的临床和生化参数。它们都没有足够的良好,可以安全地在日常临床实践中的各种情况下进行。尽管有严重的局限性,但趋势也倾向于使用估计的GFR(EGFR)作为临床研究中的“硬”临床终点。这增加了误解的风险,并导致数据不一定支持的结论。最后,在研究简短的研究概述中提到了测试药物毒性的新方法和使用药理学载体的使用,以修复正确的剂量;本报告中还提到了使用EGFR而不是MGFR遇到的可能存在的问题。 (c)2017年S. Karger AG,巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号